• AxoGen's Return on Invested Capital (ROIC) of 2.07% is significantly lower than its Weighted Average Cost of Capital (WACC) of 8.72%, indicating inefficient capital utilization.
• Assembly Biosciences, Inc. exhibits the highest inefficiency in capital utilization with a ROIC of -127.67% and a WACC of 6.45%.

AxoGen, Inc. (NASDAQ:AXGN) is a company that specializes in developing and marketing surgical solutions for peripheral nerve injuries. The company operates in the healthcare sector, focusing on products that help repair and protect nerves. AxoGen's competitors include companies like AtriCure, Inc., Tactile Systems Technology, Inc., BioLife Solutions, Inc., AnaptysBio, Inc., and Assembly Biosciences, Inc.

In evaluating AxoGen's financial performance, the Return on Invested Capital (ROIC) is a key metric. AxoGen's ROIC is 2.07%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 8.72%. This indicates that AxoGen is not generating returns that exceed its cost of capital, which is a concern for investors looking for efficient capital utilization.

Comparing AxoGen to its peers, AtriCure, Inc. has a negative ROIC of -6.47% and a WACC of 11.01%, resulting in a ROIC to WACC ratio of -0.59. This suggests that AtriCure is also struggling to generate returns above its cost of capital. Similarly, BioLife Solutions, Inc. and AnaptysBio, Inc. have negative ROICs of -4.85% and -28.56%, respectively, with WACCs of 12.57% and 9.10%.

In contrast, Assembly Biosciences, Inc. has a significantly negative ROIC of -127.67% and a WACC of 6.45%, leading to a ROIC to WACC ratio of -19.80, highlighting its inefficiency in capital utilization.